Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.40 |
| ▸ | ABL1 | P00519 | 7/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15104129 | 0.94 | SCN3A (0.38) | SCN3AABL1SCN5ASCN9AKDM4E | |
| SCHEMBL15104179 | 0.88 | SCN3A (0.36) | SCN3AABL1SCN5ASCN9AKDM4E | |
| SCHEMBL15104480 | 0.87 | SCN3A (0.34) | SCN3AABL1SCN5ASCN9AKDM4E | |
| SCHEMBL13504193 | 0.86 | SCN3A (0.38) | SCN3AABL1SCN5ASCN9AKDM4E | |
| SCHEMBL3756302 | 0.84 | GCK (0.39) | SCN3ASCN5ASCN9AKDM4ENPC1 | |
| SCHEMBL15104319 | 0.81 | PTGER3 (0.33) | SCN3AABL1GRM4 | |
| SCHEMBL13504170 | 0.81 | SCN3A (0.36) | SCN3ASCN5ASCN9AMEN1HPGD | |
| SCHEMBL2661013 | 0.80 | GRM4 (0.36) | SCN3AMEN1NPC1CYP2C9HPGD | |
| SCHEMBL2660789 | 0.80 | POLB (0.38) | KDM4EMAPTPOLB | |
| SCHEMBL15104475 | 0.79 | POLB (0.34) | ABL1GRM4PDPK1POLBCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299115-B2 | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2012-10-30 | — | — | US | disclosed |
| US-8299115-B2 | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2012-10-30 | — | — | US | disclosed |
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, PCK1, GCKR | SCN3A 1892/4885ABL1 3745/4885SCN5A 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.